Hunan Hansen Pharmaceutical (002412) Stock Overview
Engages in the production and sale of traditional Chinese preparations in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
002412 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Hunan Hansen Pharmaceutical Co., Ltd. Competitors
Zhejiang Cheng Yi Pharmaceutical
ShanXi C&Y Pharmaceutical GroupLTD
Shaanxi Panlong Pharmaceutical Group Limited By Share
Zhejiang Haisen Pharmaceutical
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.16 |
| 52 Week High | CN¥8.60 |
| 52 Week Low | CN¥5.66 |
| Beta | 0.37 |
| 1 Month Change | 8.16% |
| 3 Month Change | -3.37% |
| 1 Year Change | 21.77% |
| 3 Year Change | 2.29% |
| 5 Year Change | 15.67% |
| Change since IPO | 12.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002412 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.1% | -5.6% | -2.3% |
| 1Y | 21.8% | 0.5% | 33.8% |
Return vs Industry: 002412 exceeded the CN Pharmaceuticals industry which returned 0.5% over the past year.
Return vs Market: 002412 underperformed the CN Market which returned 33.8% over the past year.
Price Volatility
| 002412 volatility | |
|---|---|
| 002412 Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 002412 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002412's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1,675 | Zhengqing Liu | www.hansenzy.com |
Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers digestive system medicines; cardiovascular and cerebrovascular medicines; kidney-tonifying and urine-reducing medicines; trauma medicines; diagnostic medicines, etc. It provides medicines in injection, mixture, tablet, capsule, granule, syrup, decoction, tincture, and pill forms. Hunan Hansen Pharmaceutical Co., Ltd.
Hunan Hansen Pharmaceutical Co., Ltd. Fundamentals Summary
| 002412 fundamental statistics | |
|---|---|
| Market cap | CN¥3.60b |
| Earnings (TTM) | CN¥172.02m |
| Revenue (TTM) | CN¥1.05b |
Is 002412 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002412 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.05b |
| Cost of Revenue | CN¥247.79m |
| Gross Profit | CN¥803.49m |
| Other Expenses | CN¥631.47m |
| Earnings | CN¥172.02m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.34 |
| Gross Margin | 76.43% |
| Net Profit Margin | 16.36% |
| Debt/Equity Ratio | 2.4% |
How did 002412 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/19 17:34 |
| End of Day Share Price | 2026/05/19 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hunan Hansen Pharmaceutical Co., Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Jie Yao | Everbright Securities Co. Ltd. |
| Xi Wang | Industrial Securities Co. Ltd. |